Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Front Immunol. 2023 Jan 24;13:1081163. doi: 10.3389/fimmu.2022.1081163. eCollection 2022.
Costimulation blockade targeting the CD28 pathway provides improved long-term renal allograft survival compared to calcineurin inhibitors but may be limited as CTLA-4-Ig (abatacept, belatacept) blocks both CD28 costimulation and CTLA-4 coinhibition. Directly targeting CD28 while leaving CTLA-4 intact may provide a mechanistic advantage. Fc-silent non-crosslinking CD28 antagonizing domain antibodies (dAb) are currently in clinical trials for renal transplantation. Given the current standard of care in renal transplantation at most US centers, it is likely that lymphodepletion via thymoglobulin induction therapy could be used in patients treated with CD28 antagonists. Thus, we investigated the impact of T cell depletion (TCD) on T cell phenotype following homeostatic reconstitution in a murine model of skin transplantation treated with anti-CD28dAb.
Skin from BALB/cJ donors was grafted onto C56BL/6 recipients which were treated with or without 0.2mg anti-CD4 and 10μg anti-CD8 one day prior to transplant and with or without 100μg anti-CD28dAb on days 0, 2, 4, 6, and weekly thereafter. Mice were euthanized six weeks post-transplant and lymphoid cells were analyzed by flow cytometry.
Anti-CD28dAb reversed lymphopenia-induced differentiation of memory CD4+ T cells in the spleen and lymph node compared to TCD alone. Mice treated with TCD+anti-CD28dAb exhibited significantly improved skin graft survival compared to anti-CD28dAb alone, which was also improved compared to no treatment. In addition, the expression of CD69 was reduced on CD4+ and CD8+ T cells in the spleen and lymph node from mice that received TCD+anti-CD28dAb compared to TCD alone. While a reduced frequency of CD4+FoxP3+ T cells was observed in anti-CD28dAb treated mice relative to untreated controls, this was balanced by an increased frequency of CD8+Foxp3+ T cells that was observed in the blood and kidney of mice given TCD+anti-CD28dAb compared to TCD alone.
These data demonstrate that CD28 signaling impacts the differentiation of both CD4+ and CD8+ T cells during homeostatic reconstitution following lymphodepletion, resulting in a shift towards fewer activated memory T cells and more CD8+FoxP3+ T cells, a profile that may underpin the observed prolongation in allograft survival.
与钙调磷酸酶抑制剂相比,靶向 CD28 途径的共刺激阻断可提供改善的长期肾移植存活率,但可能受到限制,因为 CTLA-4-Ig(阿巴西普、贝利尤单抗)既阻断 CD28 共刺激又阻断 CTLA-4 共抑制。直接靶向 CD28 而不破坏 CTLA-4 可能具有机制优势。目前正在进行临床试验,将 Fc 沉默非交联 CD28 拮抗结构域抗体(dAb)用于肾移植。
鉴于大多数美国中心的肾移植标准治疗,在接受 CD28 拮抗剂治疗的患者中,通过胸腺球蛋白诱导治疗进行淋巴细胞耗竭可能是可行的。因此,我们在接受抗 CD28dAb 治疗的皮肤移植小鼠模型中,研究了 T 细胞耗竭(TCD)对稳态重建后 T 细胞表型的影响。
将来自 BALB/cJ 供体的皮肤移植到 C56BL/6 受体上,受体在移植前一天接受 0.2mg 抗 CD4 和 10μg 抗 CD8,以及在第 0、2、4、6 天和每周接受 100μg 抗 CD28dAb。在移植后 6 周处死小鼠,通过流式细胞术分析淋巴细胞。
与单独 TCD 相比,抗 CD28dAb 逆转了脾和淋巴结中记忆性 CD4+T 细胞的淋巴细胞减少诱导分化。与单独使用抗 CD28dAb 相比,接受 TCD+抗 CD28dAb 治疗的小鼠皮肤移植物存活率显著提高,与未治疗相比也有所提高。此外,与单独 TCD 相比,接受 TCD+抗 CD28dAb 治疗的小鼠的脾和淋巴结中 CD4+和 CD8+T 细胞上 CD69 的表达减少。虽然与未处理的对照相比,抗 CD28dAb 治疗的小鼠中 CD4+FoxP3+T 细胞的频率降低,但与单独 TCD 相比,在接受 TCD+抗 CD28dAb 治疗的小鼠的血液和肾脏中观察到 CD8+Foxp3+T 细胞的频率增加,这一变化平衡了 CD4+FoxP3+T 细胞的频率降低。
这些数据表明,CD28 信号在淋巴细胞耗竭后的稳态重建期间影响 CD4+和 CD8+T 细胞的分化,导致活化的记忆性 T 细胞减少,CD8+FoxP3+T 细胞增多,这种表型可能是观察到移植物存活延长的基础。